Enlivex Therapeutics Ltd. (ENLV) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

High Risk

Significant dilution risk

Last updated: March 25, 2026

Risk Assessment Details

Potential Dilution: 93.01% of current shares

Recent Dilution: 896.15% (2 years)

Historical Dilution Factor: significant recent dilution

Outstanding Shares

240M

Potential Supply

220M

Additional shares possible

Splits

None

Past 2 years

Summary

ENLV currently has 237M outstanding shares. with significant dilution risk as 221M authorized shares could dilute existing holders by 93.0%. The company has significantly diluted shareholders by 896.15% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
Mar 25, 2026	20-F filing \| 237.4M shares outstanding	240M	220M
Dec 23, 2025	F-3 filing: This F-3 filing from Enlivex Therapeutics Ltd. on 2025-12-23 relates to the resale of 212,000,000 ordinary shares by selling shareholders.	24M	220M
May 02, 2025	F-3 filing: Enlivex Therapeutics Ltd. may offer to sell ordinary shares, warrants and units with an aggregate initial offering price not to exceed $300,000,000.	24M	8.8M
Apr 30, 2025	20-F filing \| 23.7M shares outstanding	24M	0
Apr 30, 2024	20-F filing \| 18.6M shares outstanding	19M	0
Apr 10, 2023	20-F filing \| 18.4M shares outstanding	18M	0
Apr 29, 2022	F-3 filing: Enlivex Therapeutics Ltd. may offer ordinary shares, warrants and units up to an aggregate initial offering price of $300,000,000.	15M	0
Apr 29, 2022	20-F filing \| 18.3M shares outstanding	18M	0
Apr 30, 2021	20-F filing \| 14.6M shares outstanding	15M	0
Apr 30, 2020	20-F filing \| 10.3M shares outstanding	10M	0

Back to ENLV Details